SCShea P. Connell

Shea P. Connell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shea P. Connell has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gene-Transcript Expression in Urine Supernatant and Urine Cell-Sediment Are Different but Equally Useful for Detecting Prostate Cancer

    by Marcelino Yazbek Hanna, Mark Winterbone, Shea P. O’connell, Mireia Olivan, Rachel Hurst, Rob Mills, Colin S. Cooper, Daniel S. Brewer, Jeremy Clark

    There is considerable interest in urine as a non-invasive liquid biopsy to detect prostate cancer (PCa). PCa-specific transcripts such as the TMPRSS2:ERG fusion gene can be found in both urine extracellular vesicles (EVs) and urine cell-sediment (Cell) but the relative usefulness of these and other genes in each fraction in PCa detection has not been fully elucidated. Urine samples from 76 men (PCa n = 40, non-cancer n = 36) were analysed by NanoString for 154 PCa-associated genes-probes, 11 tissue-specific, and six housekeeping. Comparison to qRT-PCR data for four genes (PCA3, OR51E2, FOLH1, and RPLP2) was strong (r = 0.51–0.95, Spearman p < 0.00001). Comparing EV to Cells, differential gene expression analysis found 57 gene-probes significantly more highly expressed in 100 ng of amplified cDNA products from the EV fraction, and 26 in Cells (p < 0.05; edgeR). Expression levels of prostate-specific genes (KLK2, KLK3) measured were ~20× higher in EVs, while PTPRC (white-blood Cells) was ~1000× higher in Cells. Boruta analysis identified 11 gene-probes as useful in detecting PCa: two were useful in both fractions (PCA3, HOXC6), five in EVs alone (GJB1, RPS10, TMPRSS2:ERG, ERG_Exons_4-5, HPN) and four from Cell (ERG_Exons_6-7, OR51E2, SPINK1, IMPDH2), suggesting that it is beneficial to fractionate whole urine prior to analysis. The five housekeeping genes were not significantly differentially expressed between PCa and non-cancer samples. Expression signatures from Cell, EV and combined data did not show evidence for one fraction providing superior information over the other.


  • Open Access

    A Model to Detect Significant Prostate Cancer Integrating Urinary Peptide and Extracellular Vesicle RNA Data

    by Shea P. O’connell, Maria Frantzi, Agnieszka Latosinska, Martyn Webb, William Mullen, Martin Pejchinovski, Mark Salji, Harald Mischak, Colin S. Cooper, Jeremy Clark, et al.

    There is a clinical need to improve assessment of biopsy-naïve patients for the presence of clinically significant prostate cancer (PCa). In this study, we investigated whether the robust integration of expression data from urinary extracellular vesicle RNA (EV-RNA) with urine proteomic metabolites can accurately predict PCa biopsy outcome. Urine samples collected within the Movember GAP1 Urine Biomarker study (n = 192) were analysed by both mass spectrometry-based urine-proteomics and NanoString gene-expression analysis (167 gene-probes). Cross-validated LASSO penalised regression and Random Forests identified a combination of clinical and urinary biomarkers for predictive modelling of significant disease (Gleason Score (Gs) ≥ 3 + 4). Four predictive models were developed: ‘MassSpec’ (CE-MS proteomics), ‘EV-RNA’, and ‘SoC’ (standard of care) clinical data models, alongside a fully integrated omics-model, deemed ‘ExoSpec’. ExoSpec (incorporating four gene transcripts, six peptides, and two clinical variables) is the best model for predicting Gs ≥ 3 + 4 at initial biopsy (AUC = 0.83, 95% CI: 0.77–0.88) and is superior to a standard of care (SoC) model utilising clinical data alone (AUC = 0.71, p < 0.001, 1000 resamples). As the ExoSpec Risk Score increases, the likelihood of higher-grade PCa on biopsy is significantly greater (OR = 2.8, 95% CI: 2.1–3.7). The decision curve analyses reveals that ExoSpec provides a net benefit over SoC and could reduce unnecessary biopsies by 30%.


  • Open Access

    Integration of Urinary EN2 Protein & Cell-Free RNA Data in the Development of a Multivariable Risk Model for the Detection of Prostate Cancer Prior to Biopsy

    by Shea P. Connell, Robert Mills, Hardev Pandha, Richard Morgan, Colin S. Cooper, Jeremy Clark, Daniel S. Brewer, The Movember GAP1 Urine Biomarker Consortium

    The objective is to develop a multivariable risk model for the non-invasive detection of prostate cancer prior to biopsy by integrating information from clinically available parameters, Engrailed-2 (EN2) whole-urine protein levels and data from urinary cell-free RNA. Post-digital-rectal examination urine samples collected as part of the Movember Global Action Plan 1 study which has been analysed for both cell-free-RNA and EN2 protein levels were chosen to be integrated with clinical parameters (n = 207). A previously described robust feature selection framework incorporating bootstrap resampling and permutation was applied to the data to generate an optimal feature set for use in Random Forest models for prediction. The fully integrated model was named ExoGrail, and the out-of-bag predictions were used to evaluate the diagnostic potential of the risk model. ExoGrail risk (range 0–1) was able to determine the outcome of an initial trans-rectal ultrasound guided (TRUS) biopsy more accurately than clinical standards of care, predicting the presence of any cancer with an area under the receiver operator curve (AUC) = 0.89 (95% confidence interval(CI): 0.85–0.94), and discriminating more aggressive Gleason ≥ 3 + 4 disease returning an AUC = 0.84 (95% CI: 0.78–0.89). The likelihood of more aggressive disease being detected significantly increased as ExoGrail risk score increased (Odds Ratio (OR) = 2.21 per 0.1 ExoGrail increase, 95% CI: 1.91–2.59). Decision curve analysis of the net benefit of ExoGrail showed the potential to reduce the numbers of unnecessary biopsies by 35% when compared to current standards of care. Integration of information from multiple, non-invasive biomarker sources has the potential to greatly improve how patients with a clinical suspicion of prostate cancer are risk-assessed prior to an invasive biopsy.


  • Open Access

    Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression

    by Bogdan-Alexandru Luca, Vincent Moulton, Christopher Ellis, Shea P. Connell, Daniel S. Brewer, Colin S. Cooper

    The highly heterogeneous clinical course of human prostate cancer has prompted the development of multiple RNA biomarkers and diagnostic tools to predict outcome for individual patients. Biomarker discovery is often unstable with, for example, small changes in discovery dataset configuration resulting in large alterations in biomarker composition. Our hypothesis, which forms the basis of this current study, is that highly significant overlaps occurring between gene signatures obtained using entirely different approaches indicate genes fundamental for controlling cancer progression. For prostate cancer, we found two sets of signatures that had significant overlaps suggesting important genes (p < 10−34 for paired overlaps, hypergeometrical test). These overlapping signatures defined a core set of genes linking hormone signalling (HES6-AR), cell cycle progression (Prolaris) and a molecular subgroup of patients (PCS1) derived by Non Negative Matrix Factorization (NNMF) of control pathways, together designated as SIG-HES6. The second set (designated SIG-DESNT) consisted of the DESNT diagnostic signature and a second NNMF signature PCS3. Stratifications using SIG-HES6 (HES6, PCS1, Prolaris) and SIG-DESNT (DESNT) classifiers frequently detected the same individual high-risk cancers, indicating that the underlying mechanisms associated with SIG-HES6 and SIG-DESNT may act together to promote aggressive cancer development. We show that the use of combinations of a SIG-HES6 signature together with DESNT substantially increases the ability to predict poor outcome, and we propose a model for prostate cancer development involving co-operation between the SIG-HES6 and SIG-DESNT pathways that has implication for therapeutic design.


  • Open Access

    Development of a multivariable risk model integrating urinary cell DNA methylation and cell‐free RNA data for the detection of significant prostate cancer

    by Shea P. Connell, Eve O'REilly, Alexandra Tuzova, Martyn Webb, Rachel Hurst, Robert Mills, Fang Zhao, Bharati Bapat, Colin S. Cooper, Antoinette S. Perry, et al.

    Background: Prostate cancer exhibits severe clinical heterogeneity and there is a critical need for clinically implementable tools able to precisely and noninvasively identify patients that can either be safely removed from treatment pathways or those requiring further follow up. Our objectives were to develop a multivariable risk prediction model through the integration of clinical, urine‐derived cell‐free messenger RNA (cf‐RNA) and urine cell DNA methylation data capable of noninvasively detecting significant prostate cancer in biopsy naïve patients.Methods: Post‐digital rectal examination urine samples previously analyzed separately for both cellular methylation and cf‐RNA expression within the Movember GAP1 urine biomarker cohort were selected for a fully integrated analysis (n = 207). A robust feature selection framework, based on bootstrap resampling and permutation, was utilized to find the optimal combination of clinical and urinary markers in a random forest model, deemed ExoMeth. Out‐of‐bag predictions from ExoMeth were used for diagnostic evaluation in men with a clinical suspicion of prostate cancer (PSA ≥ 4 ng/mL, adverse digital rectal examination, age, or lower urinary tract symptoms).Results: As ExoMeth risk score (range, 0‐1) increased, the likelihood of high‐grade disease being detected on biopsy was significantly greater (odds ratio = 2.04 per 0.1 ExoMeth increase, 95% confidence interval [CI]: 1.78‐2.35). On an initial TRUS biopsy, ExoMeth accurately predicted the presence of Gleason score ≥3 + 4, area under the receiver‐operator characteristic curve (AUC) = 0.89 (95% CI: 0.84‐0.93) and was additionally capable of detecting any cancer on biopsy, AUC = 0.91 (95% CI: 0.87‐0.95). Application of ExoMeth provided a net benefit over current standards of care and has the potential to reduce unnecessary biopsies by 66% when a risk threshold of 0.25 is accepted.Conclusion: Integration of urinary biomarkers across multiple assay methods has greater diagnostic ability than either method in isolation, providing superior predictive ability of biopsy outcomes. ExoMeth represents a more holistic view of urinary biomarkers and has the potential to result in substantial changes to how patients suspected of harboring prostate cancer are diagnosed.


  • Open Access

    Methodology for the At-home Collection of Urine Samples for Prostate Cancer Detection

    by Martyn Webb, Kate Manley, Mireia Olivan, Ingrid Guldvik, Malgorzata Palczynska, Rachel Hurst, Shea P Connell, Ian G Mills, Daniel S Brewer, Robert Mills, et al.

    Urine from patients with prostate cancer (PCa) contains gene transcripts that have been used for PCa diagnosis and prognosis. Historically, patient urine samples have been collected after a digital... METHOD SUMMARY The use of a commercial preservative allowed samples to be maintained at room temperature without loss of RNA quality. Harvest of cell-free RNA using a novel high-volume vacuum extra...


  • Open Access

    A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer

    by Shea P. Connell, Marcel Hanna, Frank McCarthy, Rachel Hurst, Martyn Webb, Helen Curley, Helen Walker, Rob Mills, Richard Y. Ball, Martin G. Sanda, et al.

    Objectives: To develop a risk classifier using urine‐derived extracellular vesicle ( EV )‐ RNA capable of providing diagnostic information on disease status prior to biopsy, and prognostic information for men on active surveillance ( AS ). Patients and Methods: Post‐digital rectal examination urine‐derived EV ‐ RNA expression profiles ( n = 535, multiple centres) were interrogated with a curated NanoString panel. A LASSO ‐based continuation ratio model was built to generate four prostate urine risk ( PUR ) signatures for predicting the probability of normal tissue ( PUR ‐1), D'Amico low‐risk ( PUR ‐2), intermediate‐risk ( PUR ‐3), and high‐risk ( PUR ‐4) prostate cancer. This model was applied to a test cohort ( n = 177) for diagnostic evaluation, and to an AS sub‐cohort ( n = 87) for prognostic evaluation. Results: Each PUR signature was significantly associated with its corresponding clinical category ( P < 0.001). PUR ‐4 status predicted the presence of clinically significant intermediate‐ or high‐risk disease (area under the curve = 0.77, 95% confidence interval [ CI ] 0.70–0.84). Application of PUR provided a net benefit over current clinical practice. In an AS sub‐cohort ( n = 87), groups defined by PUR status and proportion of PUR ‐4 had a significant association with time to progression (interquartile range hazard ratio [ HR ] 2.86, 95% CI 1.83–4.47; P < 0.001). PUR ‐4, when used continuously, dichotomized patient groups with differential progression rates of 10% and 60% 5 years after urine collection ( HR 8.23, 95% CI 3.26–20.81; P < 0.001). Conclusion: Urine‐derived EV‐ RNA can provide diagnostic information on aggressive prostate cancer prior to biopsy, and prognostic information for men on AS . PUR represents a new and versatile biomarker that could result in substantial alterations to current treatment of patients with prostate cancer.


  • Open Access

    PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation

    by Simon J. Wilson, Fraz A. Ismat, Zhaoqing Wang, Michael Cerra, Hafid Narayan, Jennifer Raftis, Timothy J. Gray, Shea Connell, Samira Garonzik, Xuewen Ma, et al.

    Objective—: BMS-986120 is a novel first-in-class oral PAR4 (protease-activated receptor 4) antagonist with potent and selective antiplatelet effects. We sought to determine for the first time, the effect of BMS-986120 on human ex vivo thrombus formation. Approach and Results—: Forty healthy volunteers completed a phase 1 parallel-group PROBE trial (Prospective Randomized Open-Label Blinded End Point). Ex vivo platelet activation, platelet aggregation, and thrombus formation were measured at 0, 2, and 24 hours after (1) oral BMS-986120 (60 mg) or (2) oral aspirin (600 mg) followed at 18 hours with oral aspirin (600 mg) and oral clopidogrel (600 mg). BMS-986120 demonstrated highly selective and reversible inhibition of PAR4 agonist peptide (100 μM)-stimulated P-selectin expression, platelet-monocyte aggregates, and platelet aggregation ( P 2 /mm) at high shear was reduced by 29.2% (95% confidence interval, 18.3%–38.7%; P P =0.002) at 24 hours. Reductions in thrombus formation were driven by a decrease in platelet-rich thrombus deposition: 34.8% (19.3%–47.3%; P P =0.016) at 24 hours. In contrast to aspirin alone, or in combination with clopidogrel, BMS-986120 had no effect on thrombus formation at low shear ( P =nonsignificant). BMS-986120 administration was not associated with an increase in coagulation times or serious adverse events. Conclusions—: BMS-986120 is a highly selective and reversible oral PAR4 antagonist that substantially reduces platelet-rich thrombus formation under conditions of high shear stress. Our results suggest PAR4 antagonism has major potential as a therapeutic antiplatelet strategy. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT02439190.


  • Climate Change: Implications for Ecotoxicological Environmental Impact Assessment

    by Shea P. Connell, Teresa F. Fernandes, Mark G. J. Hartl

    As a consequence of increasing atmospheric CO2 and its subsequent sequestration, the oceans are undergoing changes that have not been seen for millennia, including temperature increases, ocean acidification, and localized alterations in salinity. Current methodologies for undertaking environmental-impact assessments may not be suitable for use under near-future (2100) conditions. This paper reviews and analyses what research has presently been undertaken to address these concerns. The authors find that little attention has previously been paid to chronic-exposure conditions that accurately reflect the near future, but the few available studies show that the consequences of oceanic climate change will not only be significant for marine life, but also impact humans who depend on it. The authors suggest that future research should target understanding how climate change will impact the physiological health of a wide array of species, important both economically and ecologically, going beyond the often-chosen model species and standardized testing. This information is necessary to accurately estimate the environmental risk of proposed engineering projects in changing environmental conditions.


  • The effect of zirconium doping of cerium dioxide nanoparticles on pulmonary and cardiovascular toxicity and biodistribution in mice after inhalation

    by Susan Dekkers, Mark R. Miller, Roel P. F. Schins, Isabella Römer, Mike Russ, Rob J. Vandebriel, Iseult Lynch, Marie-France Belinga-Desaunay, Eugenia Valsami-Jones, Shea P. Connell, et al.

    Development and manufacture of nanomaterials is growing at an exponential rate, despite an incomplete understanding of how their physicochemical characteristics affect their potential toxicity. Redox activity has been suggested to be an important physicochemical property of nanomaterials to predict their biological activity. This study assessed the influence of redox activity by modification of cerium dioxide nanoparticles (CeO2 NPs) via zirconium (Zr) doping on the biodistribution, pulmonary and cardiovascular effects in mice following inhalation. Healthy mice (C57BL/6 J), mice prone to cardiovascular disease (ApoE−/−, western-diet fed) and a mouse model of neurological disease (5 × FAD) were exposed via nose-only inhalation to CeO2 NPs with varying amounts of Zr-doping (0%, 27% or 78% Zr), or clean air, over a four-week period (4 mg/m3 for 3 h/day, 5 days/week). Effects were assessed four weeks post-exposure. In all three mouse models CeO2 NP exposure had no major toxicological effects apart from some modest inflammatory histopathology in the lung, which was not related to the amount of Zr-doping. In ApoE−/− mice CeO2 did not change the size of atherosclerotic plaques, but there was a trend towards increased inflammatory cell content in relation to the Zr content of the CeO2 NPs. These findings show that subacute inhalation of CeO2 NPs causes minimal pulmonary and cardiovascular effect four weeks post-exposure and that Zr-doping of CeO2 NPs has limited effect on these responses. Further studies with nanomaterials with a higher inherent toxicity or a broader range of redox activities are needed to fully assess the influence of redox activity on the toxicity of nanomaterials.